AbbVie (NYSE:ABBV) has recently seen promising developments with the release of favorable final results from the MIRASOL trial of ELAHERE, demonstrating significant improvements for women with platinum-resistant ovarian cancer. Over the last quarter, the company's share price rose by 23%, bolstered by this promising news and other product-related announcements, including ELAHERE's prior full FDA approval and regulatory progress in other regions. This positive momentum contrasts with AbbVie’s...